Literature DB >> 16202187

Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Bridget F Grant1, Deborah S Hasin, Frederick S Stinson, Deborah A Dawson, W June Ruan, Risë B Goldstein, Sharon M Smith, Tulshi D Saha, Boji Huang.   

Abstract

BACKGROUND: This study addressed the prevalences, correlates, co-morbidity and disability of DSM-IV generalized anxiety disorder (GAD) and other psychiatric disorders in a large national survey of the general population, the National Institute on Alcohol Abuse and Alcoholism's (NIAAA) National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). The study presents nationally representative data, for the first time, on prevalence, correlates, co-morbidity, and comparative disability of DSM-IV GAD.
METHOD: Data are taken from a large (n=43093) representative sample of the adult USA population.R: Prevalences of 12-month and lifetime GAD were 2.1% and 4.1%. Being female, middle-aged, widowed/separated/divorced, and low income increased risk, while being Asian, Hispanic, or Black decreased risk. GAD was highly co-morbid with substance use, and other anxiety, mood, and personality disorders. Co-morbidity in GAD was not substantially greater than for most other Axis I and II disorders. Disability and impairment in pure GAD were equivalent to pure mood disorders, but significantly greater than in pure substance use, and other anxiety and personality disorders. Individuals co-morbid for GAD and each mood disorder were more disabled than those with pure forms of GAD or each mood disorder. When co-morbid with GAD, nicotine dependence and other anxiety and personality disorders were not associated with increased disability over that associated with pure GAD, but GAD did show increased disability over that due to each of these disorders in pure form.Conclusions. Associations between GAD and Axis I and II disorders were strong and significant, with variation among specific disorders. Results strongly support GAD as an independent disorder with significant impairment and disability.

Entities:  

Mesh:

Year:  2005        PMID: 16202187     DOI: 10.1017/S0033291705006069

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  163 in total

1.  Comorbidity of generalized anxiety disorder and substance use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Analucía A Alegría; Deborah S Hasin; Edward V Nunes; Shang-Min Liu; Carrie Davies; Bridget F Grant; Carlos Blanco
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

2.  Human and economic burden of GAD, subthreshold GAD, and worry in a primary care sample.

Authors:  Sarah J Kertz; Janet Woodruff-Borden
Journal:  J Clin Psychol Med Settings       Date:  2011-09

3.  Smoking-Specific Experiential Avoidance is Indirectly Associated with Trait Worry and Smoking Processes among Treatment-Seeking Smokers.

Authors:  Samantha G Farris; Michael J Zvolensky; Peter J Norton; Julianna Hogan; Angela H Smith; Alexander M Talkovsky; Lorra Garey; Norman B Schmidt
Journal:  Behav Med       Date:  2014-11-14       Impact factor: 3.104

4.  Impairment and functioning in a sample of primary care patients with generalized anxiety disorder: results from the primary care anxiety project.

Authors:  Risa B Weisberg; Courtney Beard; Maria E Pagano; Kristin M Maki; Larry Culpepper; Martin B Keller
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

5.  Neurochemical, hormonal, and behavioral effects of chronic unpredictable stress in the rat.

Authors:  Brittney M Cox; Fares Alsawah; Peter C McNeill; Matthew P Galloway; Shane A Perrine
Journal:  Behav Brain Res       Date:  2011-01-28       Impact factor: 3.332

6.  [Use of resources and costs profile in patients with fibromyalgia or generalized anxiety disorder in primary care settings].

Authors:  Antoni Sicras-Mainar; Milagrosa Blanca-Tamayo; Ruth Navarro-Artieda; Javier Rejas-Gutiérrez
Journal:  Aten Primaria       Date:  2009-02-03       Impact factor: 1.137

7.  Personality disorders and the persistence of anxiety disorders: evidence of a time-of-measurement effect in NESARC.

Authors:  Alvaro Vergés; Matt G Kushner; Kristina M Jackson; Kathleen K Bucholz; Timothy J Trull; Sean P Lane; Kenneth J Sher
Journal:  J Anxiety Disord       Date:  2013-10-14

8.  Genome-wide association study of treatment response to venlafaxine XR in generalized anxiety disorder.

Authors:  Jeesun Jung; Elisabeth A Tawa; Christine Muench; Allison D Rosen; Karl Rickels; Falk W Lohoff
Journal:  Psychiatry Res       Date:  2017-04-14       Impact factor: 3.222

9.  Limbic and prefrontal neural volume modulate social anxiety in children at temperamental risk.

Authors:  Eran S Auday; Koraly E Pérez-Edgar
Journal:  Depress Anxiety       Date:  2019-08       Impact factor: 6.505

10.  Nicotine withdrawal in U.S. smokers with current mood, anxiety, alcohol use, and substance use disorders.

Authors:  Andrea H Weinberger; Rani A Desai; Sherry A McKee
Journal:  Drug Alcohol Depend       Date:  2009-12-16       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.